[go: up one dir, main page]

MX2023000610A - Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. - Google Patents

Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.

Info

Publication number
MX2023000610A
MX2023000610A MX2023000610A MX2023000610A MX2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A MX 2023000610 A MX2023000610 A MX 2023000610A
Authority
MX
Mexico
Prior art keywords
compound
pharmaceutical composition
relates
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2023000610A
Other languages
English (en)
Inventor
Shuzo Watanabe
Hideaki Hara
Kentaro Ohara
Masamitsu Shimazawa
Eiji Sugaru
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2023000610A publication Critical patent/MX2023000610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere al uso de compuestos que tienen actividad inhibidora de TRPV4 o sus sales farmacéuticamente aceptables, o composiciones farmacéuticas que los contienen para la fabricación de un medicamento para prevenir o tratar una enfermedad de retina acompañada de un trastorno del flujo sanguíneo o un trastorno celular. También se refiere a un método para prevenir o tratar la enfermedad, en donde el método comprende administrar los compuestos o las composiciones farmacéuticas que los contienen a seres humanos o animales. Los compuestos, sus sales farmacéuticamente aceptables o las composiciones farmacéuticas que los contienen pueden usarse en combinación con uno o más segundos agentes activos. La presente invención se refiere a una composición farmacéutica y un kit que contiene un compuesto con actividad inhibidora de TRPV4 o una sal farmacéuticamente aceptable de éste, que se utiliza para prevenir o tratar la enfermedad. Además, se refiere a un marcador para diagnosticar una enfermedad para la que es útil el tratamiento con el compuesto, y a un método de selección de fármacos para prevenir o tratar la enfermedad.
MX2023000610A 2020-07-16 2021-07-16 Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. MX2023000610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063052572P 2020-07-16 2020-07-16
PCT/JP2021/026829 WO2022014707A1 (ja) 2020-07-16 2021-07-16 眼疾患の治療薬としてのｔｒｐｖ４阻害薬

Publications (1)

Publication Number Publication Date
MX2023000610A true MX2023000610A (es) 2023-02-13

Family

ID=79555653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000610A MX2023000610A (es) 2020-07-16 2021-07-16 Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.

Country Status (10)

Country Link
US (1) US20230255965A1 (es)
EP (1) EP4183415A4 (es)
JP (1) JPWO2022014707A1 (es)
KR (1) KR20230041680A (es)
CN (1) CN115776890A (es)
BR (1) BR112022024553A2 (es)
CA (1) CA3189206A1 (es)
MX (1) MX2023000610A (es)
TW (1) TW202216143A (es)
WO (1) WO2022014707A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120641413A (zh) * 2023-04-18 2025-09-12 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120225516A (zh) * 2023-04-18 2025-06-27 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN121175303A (zh) * 2023-04-18 2025-12-19 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2006062184A1 (ja) 2004-12-09 2006-06-15 Santen Pharmaceutical Co., Ltd. 分子内にフッ素原子を有するプロスタグランジン含有製品
US20090012011A1 (en) 2006-01-11 2009-01-08 Smithkline Beecham Corporation Novel Compounds
EP1983995A4 (en) 2006-02-17 2010-09-29 Glaxosmithkline Llc COMPOUNDS AND METHODS FOR THE TREATMENT OF DISEASES WITH TRPV4 CHANNEL RECEPTORS
JP5294601B2 (ja) 2007-09-28 2013-09-18 小林製薬株式会社 Ｔｒｐｖ４受容体抑制剤
WO2009111680A1 (en) 2008-03-07 2009-09-11 Smithline Beecham Corporation Trpv4 antagonists
WO2009146177A1 (en) 2008-04-18 2009-12-03 Smithkline Beecham Corporation Trpv4 antagonists
WO2009146182A1 (en) 2008-04-18 2009-12-03 Smithkline Beecham Corporation Trpv4 antagonists
WO2009139239A1 (ja) * 2008-05-14 2009-11-19 日本電気株式会社 窒化物半導体レーザ及びその製造方法
WO2010011914A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
WO2010011912A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
WO2011091407A1 (en) 2010-01-25 2011-07-28 Glaxosmithkline Llp Trpv4 antagonists
WO2011091410A1 (en) 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
US8658636B2 (en) 2010-03-23 2014-02-25 GlaxoSmithKline, LLC TRPV4 antagonists
WO2011119704A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
WO2011119693A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
WO2011119694A1 (en) 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists
JP5971657B2 (ja) 2011-04-20 2016-08-17 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
JP5969015B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JO3154B1 (ar) 2011-06-17 2017-09-20 Glaxosmithkline Llc عوامل مضادة لـ trpv4
JP5969016B2 (ja) 2011-06-17 2016-08-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JPWO2013146754A1 (ja) 2012-03-27 2015-12-14 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2013169396A1 (en) 2012-05-11 2013-11-14 The University Of Utah Research Foundation Compounds with trpv4 activity, compositions and associated methods thereof
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
WO2015199206A1 (ja) 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
RU2018144774A (ru) 2016-05-19 2020-06-19 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Антагонист trpv4
JP7106528B2 (ja) 2016-09-20 2022-07-26 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド Ｔｒｐｖ４拮抗薬
EP3515889A1 (en) 2016-09-20 2019-07-31 GlaxoSmithKline Intellectual Property (No. 2) Limited Trpv4 antagonists
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
MX2017011166A (es) 2017-08-31 2019-03-07 Univ Mexico Nac Autonoma Uso de los farmacos antagonistas del canal ionico transient receptor potential vaniloid 4 (trpv4) para el tratamiento del edema macular.
JP7195067B2 (ja) 2018-06-20 2022-12-23 花王株式会社 ロズマリン酸誘導体又はその塩
WO2021170811A1 (en) * 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
US20230339934A1 (en) * 2020-04-30 2023-10-26 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists

Also Published As

Publication number Publication date
KR20230041680A (ko) 2023-03-24
CN115776890A (zh) 2023-03-10
BR112022024553A2 (pt) 2023-01-24
TW202216143A (zh) 2022-05-01
WO2022014707A1 (ja) 2022-01-20
US20230255965A1 (en) 2023-08-17
EP4183415A1 (en) 2023-05-24
CA3189206A1 (en) 2022-01-20
EP4183415A4 (en) 2024-07-17
JPWO2022014707A1 (es) 2022-01-20

Similar Documents

Publication Publication Date Title
US20220071949A1 (en) Combinations of cannabinoids and n-acylethanolamines
US20130029989A1 (en) Topical treatments for pain
MX2023000610A (es) Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
CA3048429A1 (en) Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
CA2831054A1 (en) Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
CN102470124A (zh) 细胞保护剂
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
BR112021026369A2 (pt) Derivados de 2h-indazol e seu uso no tratamento de doenças
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2023227881A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
GB2619119A (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
Kuhad et al. Neuroprotective effect of sesamol and quercetin against QA induced neurotoxicity: an experimental paradigm of Huntington's disease
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
Asadi-Pooya et al. Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy
Peterson et al. Membrane stabilizers
Abramowski Chemotherapy-induced neuropathic pain
Czlonkowska THE CLINICAL DEVELOPMENT OF CEREBROLYSIN: NEW APPROACHES IN STROKE STUDIES. A COMMENTARY TO THE CARS STUDY
Gould et al. Effective long-term management of opioid-naive patients with oxymorphone extended release
Nicholson et al. Treatment of neuropathic pain with KADIAN® in poor responders to other pain medications
EA201900418A1 (ru) Средство для терапии раневых или ожоговых поражений кожи
US20250352536A1 (en) Neurorestoration compositions implementing multiple neuroplasticity inducing mechanisms of action
Ram et al. Clinico-anaesthetic changes in dogs following epidural administration of ketamine and buprenorphine